## Anne M Mills

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3681965/publications.pdf Version: 2024-02-01



ANNE M MUIS

#	Article	IF	CITATIONS
1	Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology. American Journal of Surgical Pathology, 2018, 42, 39-52.	3.7	289
2	Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer. American Journal of Surgical Pathology, 2014, 38, 1501-1509.	3.7	208
3	PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages. American Journal of Surgical Pathology, 2017, 41, 334-342.	3.7	143
4	Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clinical Cancer Research, 2015, 21, 3501-3511.	7.0	129
5	PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. American Journal of Surgical Pathology, 2017, 41, 326-333.	3.7	113
6	A Comparison of CMV Detection in Gastrointestinal Mucosal Biopsies Using Immunohistochemistry and PCR Performed on Formalin-fixed, Paraffin-embedded Tissue. American Journal of Surgical Pathology, 2013, 37, 995-1000.	3.7	108
7	Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Modern Pathology, 2019, 32, 1008-1022.	5.5	89
8	HR-HPV E6/E7 mRNA In Situ Hybridization. American Journal of Surgical Pathology, 2017, 41, 607-615.	3.7	87
9	Atypical Leiomyomas of the Uterus. American Journal of Surgical Pathology, 2013, 37, 643-649.	3.7	84
10	Lynch Syndrome Screening in the Gynecologic Tract. American Journal of Surgical Pathology, 2016, 40, e35-e44.	3.7	68
11	IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Modern Pathology, 2018, 31, 1513-1522.	5.5	68
12	Cell Cycle Regulatory Markers in Uterine Atypical Leiomyoma and Leiomyosarcoma. American Journal of Surgical Pathology, 2013, 37, 634-642.	3.7	65
13	Clinicopathologic Comparison of Lynch Syndrome–associated and "Lynch-like―Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry. American Journal of Surgical Pathology, 2016, 40, 155-165.	3.7	64
14	The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. American Journal of Surgical Pathology, 2018, 42, 183-191.	3.7	63
15	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Modern Pathology, 2017, 30, 1622-1632.	5.5	62
16	Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. Gynecologic Oncology, 2017, 144, 607-612.	1.4	61
17	Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor–Positive Subset of Triple-Negative Breast Cancers. American Journal of Surgical Pathology, 2016, 40, 1109-1116.	3.7	58
18	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. Journal of Pathology, 2020, 252, 178-188.	4.5	53

#	Article	IF	CITATIONS
19	Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer. Theranostics, 2018, 8, 2782-2798.	10.0	51
20	Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. American Journal of Surgical Pathology, 2018, 42, 1549-1555.	3.7	49
21	Endocervical Fibroblastic Malignant Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). American Journal of Surgical Pathology, 2011, 35, 404-412.	3.7	43
22	<scp>PD</scp> ‣1 and <scp>IDO</scp> expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology, 2019, 74, 256-268.	2.9	42
23	Endometrial hyperplasia. Seminars in Diagnostic Pathology, 2010, 27, 199-214.	1.5	41
24	Diagnostic Efficiency in Digital Pathology. American Journal of Surgical Pathology, 2018, 42, 53-59.	3.7	40
25	Risk Stratification By p16 Immunostaining of CIN1 Biopsies. American Journal of Surgical Pathology, 2015, 39, 611-617.	3.7	39
26	Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Modern Pathology, 2018, 31, 1282-1290.	5.5	39
27	Predictive Value of Cytokeratin 7 Immunohistochemistry in Cervical Low-grade Squamous Intraepithelial Lesion as a Marker for Risk of Progression to a High-grade Lesion. American Journal of Surgical Pathology, 2016, 40, 236-243.	3.7	37
28	Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer. American Journal of Surgical Pathology, 2018, 42, 1216-1223.	3.7	36
29	Expression of Subtype-Specific Group 1 Leiomyosarcoma Markers in a Wide Variety of Sarcomas by Gene Expression Analysis and Immunohistochemistry. American Journal of Surgical Pathology, 2011, 35, 583-589.	3.7	35
30	How we treat: risk mitigation for ABOâ€incompatible plasma in plateletpheresis products. Transfusion, 2012, 52, 2081-2085.	1.6	35
31	Osteogenic tumors of bone. Seminars in Diagnostic Pathology, 2014, 31, 21-29.	1.5	34
32	Malignant Brenner tumor of the ovary: Review and case report. Gynecologic Oncology Reports, 2017, 22, 26-31.	0.6	34
33	Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). International Journal of Gynecological Pathology, 2019, 38, 157-170.	1.4	34
34	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors. American Journal of Surgical Pathology, 2019, 43, 792-801.	3.7	28
35	Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. Modern Pathology, 2020, 33, 1182-1192.	5.5	28
36	Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecologic Oncology, 2017, 146, 34-38.	1.4	27

#	Article	IF	CITATIONS
37	TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. Modern Pathology, 2019, 32, 1168-1179.	5.5	27
38	Sclerosing Microcystic Adenocarcinoma of the Head and Neck Mucosa: A Neoplasm Closely Resembling Microcystic Adnexal Carcinoma. Head and Neck Pathology, 2016, 10, 501-508.	2.6	26
39	LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy. International Journal of Gynecological Pathology, 2020, 39, 203-212.	1.4	26
40	Expanding Opportunities for Professional Development: Utilization of Twitter by Early Career Women in Academic Medicine and Science. JMIR Medical Education, 2018, 4, e11140.	2.6	26
41	Are Women With Endocervical Adenocarcinoma at Risk for Lynch Syndrome? Evaluation of 101 Cases Including Unusual Subtypes and Lower Uterine Segment Tumors. International Journal of Gynecological Pathology, 2012, 31, 463-469.	1.4	25
42	Lynch Syndrome. Surgical Pathology Clinics, 2016, 9, 201-214.	1.7	25
43	HPV E6/E7 mRNA In Situ Hybridization in the Diagnosis of Cervical Low-grade Squamous Intraepithelial Lesions (LSIL). American Journal of Surgical Pathology, 2018, 42, 192-200.	3.7	23
44	MHC Class I Loss in Triple-negative Breast Cancer. American Journal of Surgical Pathology, 2021, 45, 701-707.	3.7	23
45	Androgen Receptor Expression in Endometrial Carcinoma. International Journal of Gynecological Pathology, 2018, 37, 167-173.	1.4	22
46	CK7 Immunohistochemistry as a Predictor of CIN1 Progression. American Journal of Surgical Pathology, 2017, 41, 143-152.	3.7	21
47	Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia. American Journal of Surgical Pathology, 2020, 44, 1184-1191.	3.7	18
48	Mismatch Repair Deficiency in Uterine Carcinosarcoma. American Journal of Surgical Pathology, 2020, 44, 782-792.	3.7	18
49	Mesonephric-like Endometrial Carcinoma. American Journal of Surgical Pathology, 2022, 46, 921-932.	3.7	17
50	Mucinous Ovarian Tumors. Surgical Pathology Clinics, 2019, 12, 565-585.	1.7	16
51	Neurofibrosarcoma Revisited. American Journal of Surgical Pathology, 2021, 45, 638-652.	3.7	16
52	Smooth Muscle Tumors of the Female Genital Tract. Surgical Pathology Clinics, 2009, 2, 625-677.	1.7	15
53	Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status. International Journal of Gynecological Pathology, 2020, 39, 558-566.	1.4	15
54	From slide sets to sound bites: teaching and learning pathology in the digital age. Journal of the American Society of Cytopathology, 2014, 3, 183-187.	0.5	14

#	Article	IF	CITATIONS
55	Mucinous Differentiation With Tumor Infiltrating Lymphocytes Is a Feature of Sporadically Methylated Endometrial Carcinomas. International Journal of Gynecological Pathology, 2017, 36, 205-216.	1.4	13
56	Emerging biomarkers in ovarian granulosa cell tumors. International Journal of Gynecological Cancer, 2019, 29, 560-565.	2.5	13
57	MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition. Modern Pathology, 2021, 34, 627-636.	5.5	13
58	Evaluation of ProExC as a Prognostic Marker in Oropharyngeal Squamous Cell Carcinomas. American Journal of Surgical Pathology, 2012, 36, 1158-1164.	3.7	11
59	Laboratory-Developed L1 Sequencing and Type-Specific, Real-Time Polymerase Chain Reaction for the Detection and Typing of Human Papillomaviruses in Formalin-Fixed, Paraffin-Embedded Tissues. Archives of Pathology and Laboratory Medicine, 2013, 137, 50-54.	2.5	11
60	Parasitism as a potential contributor to massive clam mortality at the Blake Ridge Diapir methane-hydrate seep. Journal of the Marine Biological Association of the United Kingdom, 2005, 85, 1489-1497.	0.8	10
61	The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia. International Journal of Gynecological Pathology, 2022, 41, 113-121.	1.4	8
62	Financial Health for the Pathology Trainee: Fiscal Prevention, Diagnosis, and Targeted Therapy for Young Physicians. Archives of Pathology and Laboratory Medicine, 2018, 142, 12-15.	2.5	7
63	HPV RNA in situ hybridization can inform cervical cytologyâ€histology correlation. Cancer Cytopathology, 2018, 126, 533-540.	2.4	7
64	A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 473-482.	2.3	7
65	Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases. Head and Neck Pathology, 2021, 15, 163-168.	2.6	7
66	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. Modern Pathology, 2022, 35, 142-151.	5.5	7
67	Putative precancerous lesions of vulvar squamous cell carcinoma. Seminars in Diagnostic Pathology, 2021, 38, 27-36.	1.5	7
68	β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas. International Journal of Gynecological Cancer, 2020, 30, 993-999.	2.5	6
69	PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas. International Journal of Gynecological Pathology, 2021, 40, 563-574.	1.4	6
70	Atypical Endometrial Hyperplasia and Well Differentiated Endometrioid Adenocarcinoma of the Uterine Corpus. Surgical Pathology Clinics, 2011, 4, 149-198.	1.7	5
71	Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population. Human Pathology, 2018, 82, 20-31. ————————————————————————————————————	2.0	5
72	Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas. Human Pathology, 2018, 82, 282-288.	2.0	5

#	Article	IF	CITATIONS
73	Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes. Gynecologic Oncology, 2019, 152, 119-126.	1.4	5
74	"What Do You Mean It's Not Cancer?―A Review of Autoimmune and Systemic Inflammatory Diseases Involving the Breast. Journal of Breast Imaging, 2021, 3, 612-625.	1.3	4
75	PD-L1 Interpretation in Cervical Carcinomas: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. International Journal of Gynecological Pathology, 2021, 40, 1-4.	1.4	4
76	Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy. Frontiers in Oncology, 2022, 12, 801764.	2.8	4
77	Extraosseous Gaucher cell deposition without adjacent bone involvement. Skeletal Radiology, 2014, 43, 1495-1498.	2.0	3
78	p16 Immunohistochemistry Interpretation by Nonpathologists as an Accurate Method for Diagnosing Cervical Precancer and Cancer. Journal of Lower Genital Tract Disease, 2015, 19, 207-211.	1.9	3
79	MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status. International Journal of Gynecological Pathology, 2022, 41, 1-11.	1.4	3
80	Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget, 2018, 9, 8972-8984.	1.8	3
81	PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall. International Journal of Gynecological Pathology, 2022, Publish Ahead of Print, .	1.4	2
82	The pap smear caught it!: Harmonizing the findings of an abnormal pap smear and a right ovarian mass. Diagnostic Cytopathology, 2015, 43, 1039-1041.	1.0	1
83	PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions. Gynecologic Oncology Reports, 2017, 20, 135-136.	0.6	1
84	Endometrial Carcinoma. , 2019, , 455-513.		1
85	Hereditary Endometrial Carcinoma. Molecular Pathology Library, 2017, , 169-186.	0.1	1
86	Malignant Phyllodes Tumor of the Breast: A Case Study. Clinical Journal of Oncology Nursing, 2014, 18, 595-597.	0.6	0
87	Man With Hypoechoic Lesion Abutting the Pancreas. JAMA Surgery, 2014, 149, 393.	4.3	0
88	Human papillomavirus cytopathic effect in the urine of a 76â€yearâ€old man. Diagnostic Cytopathology, 2020, 48, 489-490.	1.0	0
89	Cervical Squamous Intraepithelial Lesions. , 2017, , 91-114.		0

90 Epithelial Malignant Tumors of the Cervix: Squamous Carcinoma. , 2021, , 137-167.

0